The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Increasing Risk of Relapse after Treatment of Clostridium difficile Colitis in Quebec, Canada
Open accessAbstract
Background.Clinicians who treat patients with Clostridium difficile-associated diarrhea (CDAD) in Quebec, Canada, have noted an apparent increase in the proportion of patients who experience relapse. Methods.To determine whether there was an increase in the frequency of treatment failure and of recurrence of CDAD after treatment, we reviewed data on cases that had been diagnosed in a hospital in the province of Quebec during the period 1991-2004.The frequency of recurrences within 60 days after the initial diagnosis was measured using Kaplan-Meier analysis, and Cox regression was used for multivariate analysis.Results.Among patients who had initially been treated with metronidazole, the proportion whose regimens were switched to vancomycin or for whom vancomycin was added because of a disappointing response did not vary between 1991 and 2002 (66 [9.6%] of 688 patients overall) but more than doubled in 2003-2004 (112 [25.7%] of 435;).Among 845 patients treated with metronidazole only, the 60-day probability of recurrence P !.001increased dramatically in 2003-2004 (47.2%), compared with 1991-2002 (20.8%; ).During 1991-2002, P !.001 the probabilities of recurrence were 20.0%, 13.8%, and 28.9% among individuals aged 0-17, 18-64, and у65 years, respectively; during 2003-2004, the probabilities were 25.0%, 27.1%, and 58.4%, respectively. Conclusion.In 2003-2004, there was an increase in the proportion of patients with CDAD believed, by their attending physicians, to have experienced metronidazole treatment failure, as well as an increase in the frequency of post-metronidazole therapy recurrences, especially among elderly persons.Clostridium difficile was identified as the etiological agent of pseudomembranous colitis in 1978 [1].Early studies claimed that metronidazole was as effective as oral vancomycin for therapy [2,3], and the former became the standard first-line treatment for this common cause of nosocomial infectious diarrhea.After recommendations were made by the Centers for Disease Control and Prevention to avoid the use of vancomycin in the hope of slowing down the emergence of vancomycin-resistant pathogens [4], metronidazole started to be administered to the overwhelming majority of patients with C. difficile-associated diarrhea (CDAD).Unfortunately, 5%-35% of patients experience a recurrence of CDAD, regardless of whether metronida-
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Principles and Practice of Infectious Diseases.
(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-9-818_5 · Cited by 12,025
The American Journal of Gastroenterology
(2003) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2003.80003397.x · Cited by 2,196
Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia
Bartlett, J. G., Chang, T. W., Gurwith, M., Gorbach, S. L., & Onderdonk, A. B. (1978) · New England Journal of Medicine · doi:10.1056/nejm197803092981003 · Cited by 1,374
Antibiotic-Associated Diarrhea
Bartlett, J. G. (2002) · New England Journal of Medicine · doi:10.1056/nejmcp011603 · Cited by 1,197
Pepin, J. (2004) · Canadian Medical Association Journal · doi:10.1503/cmaj.1041104 · Cited by 1,128
Self-citationAsymptomatic Carriage of Clostridium difficile and Serum Levels of IgG Antibody against Toxin A
Kyne, L., Warny, M., Qamar, A., & Kelly, C. P. (2000) · New England Journal of Medicine · doi:10.1056/nejm200002103420604 · Cited by 935
McFarland, L. V. (1994) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1994.03510480037031 · Cited by 857
Kyne, L., Warny, M., Qamar, A., & Kelly, C. P. (2001) · The Lancet · doi:10.1016/s0140-6736(00)03592-3 · Cited by 804
Teasley, D., Olson, M., Gebhard, R., Gerding, D., Peterson, L., Schwartz, M., & Lee, J. (1983) · The Lancet · doi:10.1016/s0140-6736(83)91036-x · Cited by 785
(1995) · American Journal of Infection Control · doi:10.1016/0196-6553(95)90104-3 · Cited by 709
Clostridium Difficile-Associated Diarrhea and Colitis
Gerding, D. N., Johnson, S., Peterson, L. R., Mulligan, M. E., & Silva, J. (1995) · Infection Control & Hospital Epidemiology · doi:10.1086/648363 · Cited by 631
Surawicz, C. M., McFarland, L. V., Greenberg, R. N., Rubin, M., Fekety, R., Mulligan, M. E., Garcia, R. J., Brandmarker, S., Bowen, K., Borjal, D., et al. (2000) · Clinical Infectious Diseases · doi:10.1086/318130 · Cited by 529
Wenisch, C., Parschalk, B., Hasenhundl, M., Hirschl, A. M., & Graninger, W. (1996) · Clinical Infectious Diseases · doi:10.1093/clinids/22.5.813 · Cited by 505
Clostridium difficile–Associated Diarrhea
Johnson, S., & Gerding, D. N. (1998) · Clinical Infectious Diseases · doi:10.1086/520276 · Cited by 441
Clostridium difficile Infection
Kelly, C. P., & LaMont, J. T. (1998) · Annual Review of Medicine · doi:10.1146/annurev.med.49.1.375 · Cited by 420
Clostridium difficile-associated diarrhea in adults
Poutanen, S. M. (2004) · Canadian Medical Association Journal · doi:10.1503/cmaj.1031189 · Cited by 410
Olson, M. M., Shanholtzer, C. J., Lee, J. T., & Gerding, D. N. (1994) · Infection Control & Hospital Epidemiology · doi:10.1086/646934 · Cited by 339
Bolton, R. P., & Culshaw, M. A. (1986) · Gut · doi:10.1136/gut.27.10.1169 · Cited by 320
Epidemiology, Risk Factors and Treatments for Antibiotic-Associated Diarrhea
McFarland, L. V. (1998) · Digestive Diseases · doi:10.1159/000016879 · Cited by 310
Clostridium difficile: Clinical Considerations
Bartlett, J. G. (1990) · Clinical Infectious Diseases · doi:10.1093/clinids/12.supplement_2.s243 · Cited by 209
Young, G. P., Ward, P. B., Bayley, N., Gordon, D., Higgins, G., Trapani, J. A., McDonald, M. I., Labrooy, J., & Hecker, R. (1985) · Gastroenterology · doi:10.1016/0016-5085(85)90206-9 · Cited by 171
In Vitro and In Vivo Activities of Nitazoxanide against Clostridium difficile
McVay, C. S., & Rolfe, R. D. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.9.2254-2258.2000 · Cited by 111
Citron, D. M., Merriam, C. V., Tyrrell, K. L., Warren, Y. A., Fernandez, H. T., & Goldstein, E. J. C. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.7.2334-2338.2003 · Cited by 100
Clostridium difficile infection: responses, relapses and re-infections
Wilcox, M. H., & Spencer, R. C. (1992) · Journal of Hospital Infection · doi:10.1016/0195-6701(92)90092-z · Cited by 75
Hospitals battling outbreaks of C. difficile
Eggertson, L., & Sibbald, B. (2004) · Canadian Medical Association Journal · doi:10.1503/cmaj.1040979 · Cited by 43
Cited by
Cohen, S. H., Gerding, D. N., Johnson, S., Kelly, C. P., Loo, V. G., McDonald, L. C., Pepin, J., & Wilcox, M. H. (2010) · Infection Control & Hospital Epidemiology · doi:10.1086/651706 · Cited by 2,942
Self-citationMcDonald, L. C., Gerding, D. N., Johnson, S., Bakken, J. S., Carroll, K. C., Coffin, S. E., Dubberke, E. R., Garey, K. W., Gould, C. V., Kelly, C., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/cix1085 · Cited by 2,690
Fidaxomicin versus Vancomycin for Clostridium difficile Infection
Louie, T. J., Miller, M. A., Mullane, K. M., Weiss, K., Lentnek, A., Golan, Y., Gorbach, S., Sears, P., & Shue, Y.-K. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa0910812 · Cited by 1,585
Warny, M., Pepin, J., Fang, A., Killgore, G., Thompson, A., Brazier, J., Frost, E., & McDonald, L. C. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67420-x · Cited by 1,430
Self-citationClostridium difficile— More Difficult Than Ever
Kelly, C. P., & LaMont, J. T. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0707500 · Cited by 1,313
Metadata
- Authors
- Pepin, J., Alary, M.-E., Valiquette, L., Raiche, E., Ruel, J., Fulop, K., Godin, D., & Bourassa, C.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-06-01
- Volume
- 40
- Issue
- 11
- Pages
- 1591-1597
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2163918813
- Cited by
- 570
- References
- 26
- FWCI
- 27.61
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.